Formulary

Harrow and iOR Partners Expand National Product Supply Agreement

Retrieved on: 
Wednesday, November 30, 2022
Surgery, Medical Supplies, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Optical, Marketing, COVID-19, Percussion section, Partner, Pharmacy, Safety, IOR, Acquisition, Physician, Annual report, Accreditation, Security (finance), Research, Formulary, Needle, MKO, FDA, Principal, Pharmaceutical industry, Ophthalmology

Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, and iOR Partners, the pioneer in office-based surgery in the field of ophthalmology, today jointly announced the expansion of their national product supply agreement to provide Harrows entire formulary compounded ophthalmic products to iOR Partners expanding office-based surgery locations across the United States.

Key Points: 
  • Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, and iOR Partners, the pioneer in office-based surgery in the field of ophthalmology, today jointly announced the expansion of their national product supply agreement to provide Harrows entire formulary compounded ophthalmic products to iOR Partners expanding office-based surgery locations across the United States.
  • Our mission has always focused on making medications accessible and affordable, and working with iOR Partners, the national leader in this fast-growing area of ophthalmic surgery, represents an important and growing channel for Harrow to meet our mission.
  • iOR Partners, LLC is paving the way for the future of cataract surgery with innovative, office-based surgery suites.
  • iOR Partners is the only company dedicated to ophthalmic office-based surgery and partners with practices nationwide.

Avicanna Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market

Retrieved on: 
Tuesday, November 29, 2022
Cannabidiol, Dermatology, THC, Medical cannabis, TSX, University, United States Patent and Trademark Office, R, Partnership, Social media, Solubility, Chronic pain, FSE, SKU, Pabst Blue Ribbon THC-infused seltzer, Self-microemulsifying drug delivery system, Drink, Cannabinoid, Patent, RHO, Viola, SEDAR, Nanotechnology, Gastrointestinal tract, News, Wellness, Shoppers Drug Mart, Absorption, Risk, Formulary, InFluid Software, Fine chemical, Television, Pharmaceutical industry, Research

TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce the commercialization of patent-pending, water-soluble technology Influid with an initial Viola branded beverage infuser SKU for the Canadian market.

Key Points: 
  • Our research team continues to innovate and deliver new formulations with consumer experience in mind and we are excited to progress our proprietary water-soluble technology from the lab into initial commercial channels.
  • The initial commercialization of the technology was launched under the Viola brand in Ontario as a Water-Soluble THC Infuser.
  • Avicanna is currently evaluating in-vivo pharmacokinetic profiles of its Influid technology in partnership with Dr. Jibran Khokhar at the University of Guelph.
  • Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments.

Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States

Retrieved on: 
Thursday, November 17, 2022
Dermatology, PDE4, Patient, Express, Express Scripts, Dermatitis, Pharmacy, Risk, Formulary, Psoriasis, Atopic dermatitis, Health insurance

Express Scripts commercial national formularies provide access to more than 26 million commercial lives in the United States.

Key Points: 
  • Express Scripts commercial national formularies provide access to more than 26 million commercial lives in the United States.
  • Ensuring affordable access to ZORYVE is of the utmost priority for Arcutis.
  • The inclusion of ZORYVE on Express Scripts national formularies means that our next-generation topical PDE4 inhibitor is now available as a new topical treatment option for millions of adults and adolescents in the United States living with plaque psoriasis, said Frank Watanabe, President and CEO of Arcutis.
  • Were excited by our progress to date and our ability to secure this coverage for ZORYVE with Express Scripts national formularies prior to the end of the year.

Avicanna Reports Q3 2022 Financial Statement

Retrieved on: 
Monday, November 14, 2022
Transfer, Online, Toronto Stock Exchange, Medical cannabis research, SG, Patent, Dermatology, Growth, SKU, R, Absorption, Offering, Partnership, News, Social media, Research, New England News Collaborative, Incidence, University, Stock, Cannabinoid, Chronic pain, Pain management, FSE, Health, Formulary, Cannabidiol, TSX, Wellness, SEDAR, Neurology, Knowledge, Risk, Q3, Medical cannabis, Administration, RHO, Cannabis, Fine chemical, Pharmaceutical industry, Epilepsy, Seizure

TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

Key Points: 
  • TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
  • ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS
    TORONTO, November 14, 2022 (GLOBE NEWSWIRE) Avicanna Inc. (Avicanna or the Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce the filing of its interim financial statements for the three-month period ending September 30, 2022 (Q3 2022).
  • The process of technical transfer and product re-registrations however, resulted in short term stocking gaps and lower than expected revenues in late Q2 and Q3.
  • Ventures, Inc. for Avicanna to utilize its existing scientific platform and drug delivery systems to develop and commercialize Psilly branded functional fungi-based products.

Avicanna Announces Closing of Non-Brokered Private Placement

Retrieved on: 
Friday, November 11, 2022
Social media, RHO, Offering, SEDAR, R, Company, FOR, Risk, Unit, Health, Toronto Stock Exchange, GLOBE, Research, TSX, FSE, Dermatology, Prospectus, Chronic pain, NOT, News, Cannabidiol, Absorption, Wellness, Formulary, Security (finance), Fine chemical, Pharmaceutical industry

TORONTO, Nov. 11, 2022 (GLOBE NEWSWIRE) --  Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has closed a non-brokered private placement offering of 1,790,750 ‎‎units of the Company (the “Units”) at a price of $0.35 per Unit for aggregate gross proceeds of approximately $626,762.50 (the “Offering”). Each Unit is comprised of one common share in the capital of the Company (each, a “Unit Share”) and one-half of one (0.5) common share purchase warrant of the Company (each whole warrant, a “Warrant”); and, each Warrant shall entitle the holder thereof to acquire one (1) common share in the capital of the Company at an exercise price of $0.40 per share, subject to adjustment in certain events, until November 10, 2025.

Key Points: 
  • Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments.
  • These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders.
  • For more information about Avicanna, visit www.avicanna.com, contact Ivana Maric by email at [email protected] or follow us on social media on LinkedIn , Twitter , Facebook or Instagram .
  • The statements in this news release are made as of the date of this release.

Transcarent Selects Prescryptive Health to Power a New, Different and Better Integrated Pharmacy Experience

Retrieved on: 
Thursday, November 3, 2022
Software, Telemedicine, Virtual Medicine, Pharmaceutical, Health, Data Management, Health Technology, Technology, Mobile, Wireless, Formulary, Health, CEO, Pharmacy, Pharming, Pharmacist, Prescription, Patient, Partnership, Health insurance, Transcare EMS

Transcarent Pharmacy Care empowers Transcarent Members and their families with an entirely different consumer-directed experience that truly transforms their health and care journey and provides, for the first time, employers and health systems with maximum control over their formulary, benefit designs, and data.

Key Points: 
  • Transcarent Pharmacy Care empowers Transcarent Members and their families with an entirely different consumer-directed experience that truly transforms their health and care journey and provides, for the first time, employers and health systems with maximum control over their formulary, benefit designs, and data.
  • Transcarent is partnering with Prescryptive to create a transparent, connected care experience that aligns with our mission to break down healthcare silos and empower our Members on their health and care journey.
  • Transcarent is a new, different, and better health and care experience that puts health consumers in charge and is aligned with the people who pay for their care.
  • Transcarent takes accountability for results offering at-risk pricing models and transparent impact reporting to align incentives towards measurably better experience, better health, and lower costs.

Transcarent Selects Prescryptive Health to Power a New, Different and Better Integrated Pharmacy Experience

Retrieved on: 
Thursday, November 3, 2022
PALO, CEO, Solution, Pharming, Prescription, Formulary, Health, Pharmacy, Pharmacist, Partnership, Patient, Health insurance, Transcare EMS

REDMOND, Wash. and PALO ALTO, Calif., Nov. 3, 2022 /PRNewswire/ -- Transcarent, a new, different and better health and care experience company that puts people back in charge of their care and aligns with the companies who pay for care and Prescryptive Health, a healthcare technology company on a mission to rewrite the script for the U.S. pharmaceutical market, announced today a partnership to provide the industry's most immersive, intelligent, and individualized pharmacy care experience. 

Key Points: 
  • Transcarent Pharmacy Care empowers Transcarent Members and their families with an entirely different consumer-directed experience that truly transforms their health and care journey and provides, for the first time, employers and health systems with maximum control over their formulary, benefit designs, and data.
  • Transcarent is partnering with Prescryptive to create a transparent, connected care experience that aligns with our mission to break down healthcare silos and empower our Members on their health and care journey."
  • To learn more about Prescryptive Health, visit www.prescryptive.com
    Transcarent is a new, different, and better health and care experience that puts health consumers in charge and is aligned with the people who pay for their care.
  • Transcarent takes accountability for results offering at-risk pricing models and transparent impact reporting to align incentives towards measurably better experience, better health, and lower costs.

Avicanna Announces Extension of Term Loan

Retrieved on: 
Monday, October 31, 2022
RHO, Formulary, Dermatology, SEDAR, News, GLOBE, Wellness, R, FSE, Absorption, TSX, Chronic pain, Social media, Term loan, Cannabidiol, Company, Health, Risk, Security (finance), Pharmaceutical industry

TORONTO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid based products, announces that it has entered into a extension agreement (the Extension Agreement) in connection with its senior secured term loan previously announced on August 19, 2021 (the Term Loan).

Key Points: 
  • TORONTO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid based products, announces that it has entered into a extension agreement (the Extension Agreement) in connection with its senior secured term loan previously announced on August 19, 2021 (the Term Loan).
  • In accordance with the Extension Agreement, the maturity date of the Term Loan was extended by five months, from October 19, 2022 to March 19, 2023 (the New Maturity Date).
  • Pursuant to the Extension Agreement, the Company will continue to make interest payments as required by the original loan agreement in respect of the Term Loan, and will also make monthly repayments of principal beginning in November, 2022 and ending in February, 2023, following which the outstanding principal on the Term Loan will come due on the New Maturity Date.
  • The Term Loan continues to bear interest at 5% per annum, calculated monthly.

Comparing Plans Can Save You Money

Retrieved on: 
Monday, October 31, 2022
Medicaid, Formulary, Hearing, Adult, Health, Human services, Income, Inflation, Medicare Part D coverage gap, SHIP, Prescription, Advisory Committee, Microsoft family features, Medicare (United States), Advisory Committee on Immunization Practices, TTY, Medicare Part D, Vaccine, Office of Inspector General, U.S. Department of Health and Human Services, Review, Medicare, Revolution, CDC, Language, Part, Insulin, Shingles, Health insurance

MISSION, Kan., Oct. 31, 2022 /PRNewswire/ -- (Family Features) Medicare Open Enrollment is your chance to compare your choices for the year ahead and to see if you could save money in 2023 on your health or prescription drug plans or even find extra benefits. Don't delay – Open Enrollment ends December 7th.

Key Points: 
  • You can do a side-by-side comparison of plan coverage, costs and quality ratings to help you more easily see the differences between plans.
  • To compare plans and find the best coverage to fit your needs:
    Find plans at Medicare.gov and do side-by-side comparisons of costs and coverage.
  • These programs could help you save money on health and prescription drug costs and could reduce your Part B premium from $165 to $0.
  • To get help comparing plans if you take insulin, call 1-800-MEDICARE or contact your local State Health Insurance Assistance Program (SHIP).

The Senior Citizens League Says, "You Better Check Your Medicare Drug Plan"

Retrieved on: 
Monday, October 31, 2022
Insurance, Social Security, Policy, Insulin glargine/lixisenatide, Social, Diabetes, Thought, Insulin, Friends, Association, Formulary, Medicare Advantage, Johnson, Medicare Part D, Retired Enlisted Association, Prescription, SHIP, Insulin lispro, Elijah Cummings Lower Drug Costs Now Act, Ageing, Blood pressure, Folate, CVS, Walgreens, Wind, Health insurance, Pharmaceutical industry, Citizenship, Insulin glargine, Walmart, Medicare

WASHINGTON, Oct. 26, 2022 /PRNewswire-PRWeb/ -- The recently enacted Inflation Reduction Act requires Medicare Part D plans to cap insulin costs at $35 per month per covered prescription starting in 2023, but to get the savings, diabetic Medicare beneficiaries first need to confirm that their insulin will be covered by their plan next year, warns the Senior Citizens League (TSCL). "If your insulin isn't covered by your plan, the $35 cap will not apply and you could wind up with thousands of dollars in pharmacy bills," says Mary Johnson, a Medicare, and Social Security policy analyst for The Senior Citizen League.

Key Points: 
  • For the past 17 years, Johnson has been helping friends and family check and compare their Medicare coverage options during the annual Medicare Open Enrollment Period.
  • Johnson, who has experience doing drug plan searches, immediately hit a dead end on her first search attempt using the Medicare Drug Plan Finder .
  • "The drug input in the Medicare Drug Plan Finder automatically defaults to the generic name of the drug unless the user overrides it and clicks on 'brand.'
  • With 1.2 million supporters, The Senior Citizens League is one of the nation's largest nonpartisan seniors' groups.